By Mrinalika Roy and Kamal Choudhury

(Reuters) -McKesson on Tuesday raised its profit forecast, as the U.S. drug distributor aims to focus on high-margin businesses such as cancer medicines to boost growth.

The Texas-based firm now expects adjusted earnings to range between $38.05 and $38.55 per share for fiscal 2026, up from its previous forecast of $37.10 to $37.90.

It also lifted its long-term adjusted earnings growth target to 13% to 16%, from a prior range of 12% to 14%.

McKesson’s shares rose about 3% following the announcement.

The company’s strong operational track record and disciplined execution would deliver “meaningful impact across the healthcare ecosystem,” CEO Brian Tyler said.

McKesson last week announced a reorganization of its business, including a newly defined onc

See Full Page